What is Seres Therapeutics Inc?
, a clinical-stage company, focuses on developing biotherapeutics for serious diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 14.27M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.